Maximize the efficiency of regulatory operations with five key competencies
More than a year since the COVID-19 outbreak began, the pharmaceutical industry has shifted its focus to vaccine development for infectious diseases while continuing its pre-pandemic efforts to develop novel innovations to address unmet needs across a broad spectrum of indications. Large and small firms alike are now directing top talent and resources, including regulatory, to those efforts.
At the same time, companies cannot afford to neglect the mature products that provide the revenues to fund R&D. One way to balance these conflicting demands is to streamline the regulatory maintenance of approved products. By honing these five competencies, companies can manage post-marketing regulatory requirements better and more efficiently.